Chiasma, Inc., a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CHMA
Previous Symbol
CUSIPN/A
Phone617-928-5300
Debt
Debt-to-Equity RatioN/A
Current Ratio5.64
Quick Ratio5.64
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.70 per share
Price / Book2.34
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-26,820,000.00
Net MarginsN/A
Return on Equity-54.27%
Return on Assets-46.88%
Miscellaneous
Employees16
Outstanding Shares24,430,000
Market Cap$96.99 million
OptionableNot Optionable
Chiasma (NASDAQ:CHMA) Frequently Asked Questions
What is Chiasma's stock symbol?
Chiasma trades on the NASDAQ under the ticker symbol "CHMA."
How were Chiasma's earnings last quarter?
Chiasma Inc (NASDAQ:CHMA) posted its quarterly earnings results on Thursday, August, 9th. The biotechnology company reported ($0.36) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.36) by $0.00. View Chiasma's Earnings History.
When is Chiasma's next earnings date?
Has Chiasma been receiving favorable news coverage?
Press coverage about CHMA stock has trended somewhat positive recently, according to InfoTrie. The research firm identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Chiasma earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 7.0 out of 10, indicating that recent media coverage is likely to have an impact on the company's share price in the immediate future.
Who are some of Chiasma's key competitors?
Some companies that are related to Chiasma include Zafgen (ZFGN), Achillion Pharmaceuticals (ACHN), Ra Pharmaceuticals (RARX), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Abeona Therapeutics (ABEO), ZEALAND PHARMA/S (ZEAL), Cytokinetics (CYTK), Verrica Pharmaceuticals (VRCA), American Brivision (Holding) (ABVC), Savara (SVRA), ZIOPHARM Oncology (ZIOP), Minerva Neurosciences (NERV), Seres Therapeutics (MCRB) and Kalvista Pharmaceuticals (KALV).
Who are Chiasma's key executives?
Chiasma's management team includes the folowing people:
- Mr. Mark J. Fitzpatrick, Pres, CEO, Sec. & Director (Age 55)
- Mr. Drew Enamait, VP of Fin. & Admin. and Principal Accounting Officer (Age 44)
- Dr. Gary Patou, Head of Clinical (Age 59)
- Dr. William H. Ludlam, Sr. VP of Clinical Devel. & Medical Affairs (Age 53)
- Dr. Asi Haviv DMD, VP of Clinical Devel.
When did Chiasma IPO?
(CHMA) raised $76 million in an initial public offering on Thursday, July 16th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Barclays and Cowen and Company served as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.
Who are Chiasma's major shareholders?
Chiasma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (9.73%), Nexthera Capital LP (2.61%), Point72 Asset Management L.P. (1.64%), EcoR1 Capital LLC (1.55%), Bridgeway Capital Management Inc. (0.95%) and Renaissance Technologies LLC (0.34%). Company insiders that own Chiasma stock include Roni Mamluk and Scott Minick. View Institutional Ownership Trends for Chiasma.
Which institutional investors are selling Chiasma stock?
Which institutional investors are buying Chiasma stock?
CHMA stock was bought by a variety of institutional investors in the last quarter, including Nexthera Capital LP, EcoR1 Capital LLC, Dimensional Fund Advisors LP, Citadel Advisors LLC and Renaissance Technologies LLC. View Insider Buying and Selling for Chiasma.
How do I buy shares of Chiasma?
Shares of CHMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Chiasma's stock price today?
One share of CHMA stock can currently be purchased for approximately $3.97.
How big of a company is Chiasma?
Chiasma has a market capitalization of $96.99 million. Chiasma employs 16 workers across the globe.
What is Chiasma's official website?
How can I contact Chiasma?
Chiasma's mailing address is 460 Totten Pond Road Suite 530, Waltham MA, 02451. The biotechnology company can be reached via phone at 617-928-5300 or via email at [email protected]
MarketBeat Community Rating for Chiasma (NASDAQ CHMA)
MarketBeat's community ratings are surveys of what our community members think about Chiasma and other stocks. Vote "Outperform" if you believe CHMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CHMA will underperform the S&P 500 over the long term. You may vote once every thirty days.
